Loading
Life sciences · Journal article
Nano Letters · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Nanoparticle (NP)-based drug delivery has been explored to improve the therapeutic index of anticancer agents by enhancing tumor accumulation and reducing systemic toxicity. Among active targeting approaches, cluster of differentiation 44 (CD44) has attracted attention because of its overexpression in tumor cells and tumor-associated endothelial cells and its involvement in tumor progression and therapeutic resistance. Hyaluronic acid (HA) and other glycosaminoglycan (GAG)-based nanocarriers have been developed to exploit CD44-mediated tumor targeting and cellular uptake. However, the in vivo performance of CD44-targeted NPs remains variable because of barriers such as systemic clearance, heterogeneous tumor vasculature and stroma, limited receptor accessibility, competition with endogenous ligands, and inefficient intracellular trafficking or payload release. This Letter summarizes advances in CD44-targeted NP delivery, focusing on barriers at systemic, tumor tissue, and cellular levels. We discuss barrier-informed strategies to optimize ligand presentation, improve penetration, promote intracellular payload release, and highlight translational challenges and opportunities for CD44-targeted nanomedicines.